The CEO of German pharmaceutical company BioNTech Ugur Sahin today said today (Dec 22) that he has "scientific confidence" that coronavirus vaccine developed by his company would also work on the variant detected in the UK.
Uğur Şahin told a press conference that his team had been working on trying to find out whether the vaccine worked on the UK variant or whether it would be necessary to adapt it. Results would be known within two weeks, he said.
Should the vaccine need to be adjusted for the new variant the company could do so in about six weeks, said Uğur Sahin, though regulators might have to approve the changes before the shots can be used.
"..In principle the beauty of the messenger technology is that we can directly start to engineer a vaccine which completely mimics this new mutation – we could be able to provide a new vaccine technically within six weeks.” Uğur Sahin said
BioNTech’s vaccine, developed with the US pharmaceutical company Pfizer, has been authorised for use in more than 45 countries, including Britain and the US.
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.